Dimethyl fumarate: a Janus-faced substance?

Bibliography

• Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:285-302
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128(Pt 11):2705-12
   PubMed Web of Science ®Google Scholar
• Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9(1):69-92
   PubMed Web of Science ®Google Scholar
• Witte ME, Bo L, Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009;219(2):193-204
   PubMed Web of Science ®Google Scholar
• Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics 2009;3:369-76
   PubMedGoogle Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70(12):1545-77
   PubMed Web of Science ®Google Scholar
• Carroll WM. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit. Mult Scler 2009;15(8):951-8
   PubMedGoogle Scholar
• Schweckendiek W. Treatment of psoriasis vulgaris [Article in German]. Med Monatsschr 1959;13(2):103-4
   PubMedGoogle Scholar
• Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005;11(1):43-8
   PubMed Web of Science ®Google Scholar
• Krueger G, Ellis CN. Psoriasis–recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53(1 Suppl 1):S94-100
   Google Scholar
• Nieboer C, de Hoop D, van Loenen AC, et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989;20(4):601-8
   PubMed Web of Science ®Google Scholar
• Susitaival P, Winhoven SM, Williams J, et al. An outbreak of furniture related dermatitis (‘sofa dermatitis') in Finland and the UK: history and clinical cases. J Eur Acad Dermatol Venereol 2010;24(4):486-9
   PubMedGoogle Scholar
• D'Erme AM, Bassi A, Lotti T, Gola M. Dimethyl fumarate contact dermatitis of the foot: an increasingly widespread disease. Int J Dermatol 2012;51(1):42-5
   PubMedGoogle Scholar
• Commission of the European Communities. Commission decision of 17 March 2009 requiring member states to ensure that products containing the biocide dimethylfumarate are not placed or made available on the market (2009/251/EC). Official J European Union 2009;74:32-4
   Google Scholar
• Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006;13(6):604-10
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372(9648):1463-72
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367(12):1087-97
   PubMed Web of Science ®Google Scholar
• FDA approves first oral drug to reduce MS relapses. U.S. Food and Drug Administration. 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm226755.htm [Last accessed 4 January 2013]
   Google Scholar
• FDA approves new multiple sclerosis treatment Aubagio. U.S. Food and Drug Administration. 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm [Last accessed 25 February 2013]
   Google Scholar
• Litjens NH, Burggraaf J, van Strijen et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004;58(4):429-32
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 2010;302(7):531-8
   PubMedGoogle Scholar
• Werdenberg D, Joshi R, Wolffram S, et al. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003;24(6):259-73
   PubMed Web of Science ®Google Scholar
• Nibbering PH, Thio B, Zomerdijk TP, et al. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993;101(1):37-42
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999;141(3):424-9
   PubMed Web of Science ®Google Scholar
• Talalay P, De Long MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci U S A 1988;85(21):8261-5
   PubMedGoogle Scholar
• Schmidt TJ, Ak M, Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine–preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 2007;15(1):333-42
   PubMedGoogle Scholar
• Rostami-Yazdi M, Clement B, Schmidt TJ, et al. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009;129(1):231-4
   PubMed Web of Science ®Google Scholar
• Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 2004;4:22
   PubMedGoogle Scholar
• Nibbering PH, Thio B, Bezemer AC, et al. Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes. Br J Dermatol 1997;137(1):65-75
   PubMedGoogle Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996;26(9):2067-74
   PubMed Web of Science ®Google Scholar
• Litjens NH, Rademaker M, Ravensbergen B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004;34(2):565-75
   PubMedGoogle Scholar
• Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001;116(2):203-8
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998;139(3):390-5
   PubMed Web of Science ®Google Scholar
• Stoof TJ, Flier J, Sampat S, et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001;144(6):1114-20
   PubMed Web of Science ®Google Scholar
• Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007;127(4):835-45
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121(6):1383-8
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997;234(1):19-23
   PubMed Web of Science ®Google Scholar
• Wierinckx A, Breve J, Mercier D, et al. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005;166(1-2):132-43
   PubMedGoogle Scholar
• Nelson KC, Carlson JL, Newman ML, et al. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1999;40(9):1927-35
   PubMedGoogle Scholar
• Vandermeeren M, Janssens S, Wouters H, et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001;116(1):124-30
   PubMedGoogle Scholar
• Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992;27(5 Pt 1):769-71
   PubMed Web of Science ®Google Scholar
• Devine PJ, Perreault SD, Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity. Biol Reprod 2012;86(2):27
   PubMed Web of Science ®Google Scholar
• Zubkova EV, Robaire B. Effect of glutathione depletion on antioxidant enzymes in the epididymis, seminal vesicles, and liver and on spermatozoa motility in the aging brown Norway rat. Biol Reprod 2004;71(3):1002-8
   PubMedGoogle Scholar
• Peters P, Schaefer C. Dermatological medications and local therapeutics. In: Schaefer C, Peters P, Miller R, editors. Drugs during pregnancy and lactation treatment options and risk assessment. 2nd edition. Academic Press; London, UK: 2007
   Google Scholar
• Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13(1):76-86
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134(Pt 3):678-92
   PubMed Web of Science ®Google Scholar
• Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236(2):313-22
   PubMed Web of Science ®Google Scholar
• Chen XL, Dodd G, Thomas S, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006;290(5):H1862-70
   PubMed Web of Science ®Google Scholar
• Li J, Johnson D, Calkins M, et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 2005;83(2):313-28
   PubMed Web of Science ®Google Scholar
• Vargas MR, Pehar M, Cassina P, et al. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem 2005;280(27):25571-9
   PubMedGoogle Scholar
• Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341(1):274-84
   PubMed Web of Science ®Google Scholar
• van Horssen J, Drexhage JA, Flor T, et al. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 2010;49(8):1283-9
   PubMed Web of Science ®Google Scholar
• Ghosh N, Ghosh R, Mandal SC. Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radic Res 2011;45(8):888-905
   PubMed Web of Science ®Google Scholar
• Son TG, Camandola S, Mattson MP. Hormetic dietary phytochemicals. Neuromolecular Med 2008;10(4):236-46
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011;71(5):1999-2009
   PubMedGoogle Scholar
• Lau A, Villeneuve NF, Sun Z, et al. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58(5-6):262-70
   PubMed Web of Science ®Google Scholar
• Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29(6):1235-43
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;12(8):564-71
   PubMed Web of Science ®Google Scholar
• Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON). U.S. National Institutes of Health. 2012. Available from: http://www.clinicaltrials.gov/show/NCT01351675 [Last accessed 25 February 2013]
   Google Scholar
• Bayard W, Hunziker T, Krebs A, et al. Peroral long-term treatment of psoriasis using fumaric acid derivatives [Article in German]. Hautarzt 1987;38(5):279-85
   PubMedGoogle Scholar
• Nieboer C, de Hoop D, Langendijk PN, et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990;181(1):33-7
   PubMedGoogle Scholar
• Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994;30(6):977-81
   PubMed Web of Science ®Google Scholar
• Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study [Article in Dutch]. Ned Tijdschr Geneeskd 1990;134(49):2387-91
   PubMedGoogle Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998;138(3):456-60
   PubMed Web of Science ®Google Scholar
• Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149(2):363-9
   PubMed Web of Science ®Google Scholar
• Raschka C, Koch HJ. Long-term treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 1999;18(12):738-9
   PubMedGoogle Scholar
• Fumaderm®: Summary of Product Characteristics. Fumedica Pharmaceuticals, 2003
   Google Scholar
• van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368(17):1658-9
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med 2013;368(17):1659-61
   PubMed Web of Science ®Google Scholar
• Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353(9157):964-9
   PubMed Web of Science ®Google Scholar
• Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42(5):783-93
   PubMed Web of Science ®Google Scholar
• van Walderveen MA, Barkhof F, Pouwels PJ, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46(1):79-87
   PubMedGoogle Scholar
• Macmanus DG, Miller DH, Kappos L, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2011;258(3):449-56
   PubMedGoogle Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis (Supplementary Appendix). N Engl J Med 2012
   Google Scholar
• <con-prof>Vollmer TL, Soelberg Sorensen P, Arnold DL. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis [Abstract]. Amsterdam, The Netherlands: 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; 2011
   Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis (Supplementary Appendix). N Engl J Med 2012
   Google Scholar
• Report of the scientific committee on animal nutrition on the safety of fumaric acid. European Commission. 2003. Available from: ec.europa.eu/food/fs/sc/scan/out112_en.pdf [Last accessed 17 January 2013]
   Google Scholar